Patients with Crohn's disease and ulcerative colitis face a high disease burden.
Chetan Karyekar, MD, PhD
Advertisement
VP, late development, immunology at The Janssen Pharmaceutical Companies of Johnson & Johnson.
Articles by Chetan Karyekar, MD, PhD
Advertisement